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Aberrant promoter hypermethylation of tumor-associated
genes leading to their inactivation is a common event in
many cancer types. Using a sensitive restriction-multiplex
PCR method, we studied the promoter hypermethylation
profile of the p16, p15, hMLH1, MGMT and E-cad genes in oral
squamous cell carcinoma (OSCC) of Indians. We analyzed a
total of 51 samples for the p15 tumor-suppressor gene and 99
samples for each of the remaining genes. Our studies indicate
an incidence of promoter hypermethylation of 23% each for
p16 and p15, 8% for hMLH1, 41% for MGMT and 35% for E-cad.
We observed aberrant hypermethylation of the promoter
region of at least 1 of these genes in 74.5% of cases (n  51)
for which all the 5 genes were studied. Abnormal methyl-
ation was detected in tumors irrespective of stage and loca-
tion in the oral cavity, whereas no abnormal methylation was
detectable in normal oral squamous tissues obtained from 25
OSCC patients. Detection of aberrant hypermethylation pat-
terns of cancer-associated genes listed above is therefore
suitable for diagnosis of OSCC in individuals at high risk for
this disease.
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Oral squamous cell carcinoma (OSCC) is one of the most
widely prevalent cancer types in developing countries, including
India, and is associated with tobacco and alcohol abuse.1 Although
recent research has given deeper insight into the etiology of the
disease, its occurrence as a potentially fatal disease continues
unabated. It is therefore essential to identify and develop newer
risk markers for diagnosis and therapy of OSCC.
Methylation profiling of promoter regions is essential for un-
derstanding the regulation of imprinted genes, X-chromosome
inactivation and the role of various tumor-suppressor genes in the
genesis of different types of cancer.2,3 Methylation profiling of
tumor-suppressor genes is a potentially powerful diagnostic tool
for early detection of various types of cancer.3–5 Assessment of
methylation inactivation is important in assigning functional roles
of genes and may have implications in the function of other
interacting proteins.3,6
Inactivation of several tumor-associated genes, especially tu-
mor-suppressor genes, has been attributed to aberrant hypermeth-
ylation of their promoter regions.2,3,6 We included in our study 5
tumor-suppressor genes: p16, a CDK inhibitor involved in regu-
lation of the cell cycle by the cyclin D–Rb pathway, control of
which is lost in virtually all tumor types;7 p15, another CDK
inhibitor involved in cell-cycle regulation;8 hMLH1, the human
homolog of bacterial MutL, involved in mismatch repair;9 MGMT,
the gene involved in repair of methylated guanosine residues
formed due to alkylated carcinogens; and E-cadherin, involved in
homotypic epithelial cell–cell adhesion.10 All of these genes are
known to be inactivated by methylation in various cancers.3,11
Methylation profiling of CpG sites originally involved digestion
of sample DNA using a methylation-sensitive restriction enzyme
followed by Southern hybridization7,12 or PCR using primers
flanking the restriction site.13–15 Using these assays, methylation
patterns could not be determined from very small amounts of DNA
and the occurrence of false-negatives due to degradation or loss of
DNA and false-positives due to incomplete digestion could not be
excluded.
Methylation-specific PCR (MSP) involves bisulfite modification
by deamination of unmethylated cytosines to uracil, followed by
PCR amplification using 2 sets of primers, 1 specific for the
methylated sequence and 1 for the unmethylated sequence, and, if
necessary, direct sequencing using the methylation-specific prim-
ers.16,17 This technique is widely used, and quantification of meth-
ylated alleles is possible using fluorescence-labeled primers and
light cycler equipment.18 Given all of the advantages, the assay is
difficult to optimize for all loci and expensive methods to purify
the DNA after bisulfite modification are needed.
We have developed a multiplex, PCR-based assay for the de-
tection of methylation. In this assay, we employ an appropriate
methylation-sensitive restriction enzyme (HpaII) to detect CpG
methylation in its recognition site 5CCGG 3, which is fairly
distributed in CpG islands in the promoter regions of various
genes. Using this assay, we have found that the MGMT and
E-cadherin genes are highly methylated in their promoter regions,
while the p16 and p15 genes are moderately methylated in Indian
OSCC patients.
MATERIAL AND METHODS
Sample collection and DNA isolation
Surgically resected OSCC samples were collected from Gov-
ernment Rajaji Hospital, Madurai; transferred to cold PBS; and
transported on ice to the laboratory. DNA was isolated immedi-
ately by proteinase-K digestion, followed by organic extraction.
Restriction digestion of genomic DNA
Genomic DNA (3 g) was digested initially with 5 U of HpaII
restriction enzyme (Amersham, Aylesbury, UK) in 1  supplied
buffer L for 2 hr at 37°C, and the reaction was refreshed with 10
U of HpaII incubated overnight. Phenol-chloroform extraction was
done immediately after digestion. Restriction digestion of genomic
DNA was ascertained by PCR using primers for the human protein
phosphatase gene exon 1 region, which were designed flanking the
HpaII restriction site. Absence of amplified product compared to
control indicated complete digestion.
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Primers
Promoter regions of the tumor-associated genes used in our
study were obtained from the NCBI database, and the primers were
designed flanking HpaII sites (5CCGG3) within the region re-
ported to be methylated (usually 500 bp of the transcription start
site), as shown in Table I.
FIGURE 1 – Seminested, multiplex PCR for assessment of methylation. (a) Schematic representation showing the strategy for detection of
methylation at the 5CCGG3 HpaII restriction site in the promoter region of the p16 tumor-suppressor gene. (b) Agarose gel electrophoretic
pattern of amplified products using sense, antisense and nested primers in a multiplex reaction. Lane 1, in vitro methylated p16 promoter plasmid
construct used as template; lane 2 unmethylated promoter plasmid construct; lane 3, in vitro methylated human placental DNA; lane 4, human
placental DNA; lane M, 100 bp DNA ladder.
FIGURE 2 – (a) Detection of methylation in a fraction of target sequences by the assay. PCR products electrophoresed in 2% agarose gel.
Promoter plasmid construct pSA and pNA were spiked in different ratios into 50 ng/l salmon sperm DNA, and PCR was performed. Lane 1,
pSA:pNA 1:1; lane 2, pSA:pNA 1:2: lane 3, pSA:pNA 1:3; lane 4, pSA:pNA 1:4; lane 5, pSA:pNA 1:5; lane 6, pSA:pNA 1:6; lane 7, pSA:pNA
1:7; lane 8, pSA:pNA 1:8; lane 9, pSA:pNA 0:1; lane 10, 50 ng salmon sperm DNA (carrier control); lane M, 100 bp DNA ladder. (b) Intensity
plot of the semiquantitative assay. Lanewise intensity plot of Figure 3 analyzed on an Alpha Innotech (San Leandro, CA) Image quant
gel-documentation system. SA, amplicon when sense and antisense primers were used; NA, amplicon when nested and antisense primers were
used.
TABLE I – SEQUENCE OF PRIMERS AND AMPLICONS
No. Gene Primer Sequence
M.Wt
SA/NA
(bp)
No. of HpaII
sites included
Primer
Conc. (M)
5% DMSO
requirement
1 p16
p16 S 5 GAAGAAAGAGGAGGGGCTG 3 SA-340
NA-170 2
0.2 Yes
p16 A 5 GGTCGGGTAGAGGAGGTGC 3 0.4
p16 N 5 GCGCTACCTGATTCCAATTC 3 0.2
2 p15
p15 S 5 CGAGGCGGGGCAGTGAG 3 SA-234
NA-126 2
0.4 No
p15 A 5 TCAAGAACCAGCGGGCG 3 0.2
p15 N 5 CTAGGAGACCTGGGCTCAGC 3 0.2
3 hMLH1
hMLH1 S 5 GGAGAGGAGGAGCCTGAGAAG 3 SA-392
NA-255 2
0.2 Yes
hMLH1 A 5 AGATGCTCAACGGAAGTGCCT 3 0.4
hMLH1 N 5 GAACCAATAGGAAGAGCGGAC 3 0.2
4 E-cadherin
E-cad S 5 GGCAATACAGGGAGACACAGC 3 SA-360
NA-155 1
0.2 No
E-cad A 5 GCACGGTTCTGATTCCACTG 3 0.2
E-cad N 5 GGCTCAAGCGGTCCTCTGG 3 0.4
5 MGMT
MGMT S 5 TCTTCCTGTCTCAGCCTTCC 3 SA-418
NA-253 1
0.2 No
MGMT A 5 AATTACTGTATCCCGATTCTTCTC 3 0.4
MGMT N 5 GCATAGGTGCTGAGTTGAATC 3 0.2
SA, amplicon when sense and antisense primers were used; NA, amplicon when nested and antisense primers were used.
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PCR conditions
Seminested multiplex PCRs were carried out, unless otherwise
mentioned, in a 10 l reaction using 50 ng of template DNA, 1.5
mM MgCl2, 1  PCR buffer, 200 M dNTPs, 5.0% DMSO, 0.2
M each of sense nested and 0.4 M of antisense primers and 0.25
U of Promega (Madison, WI) Taq DNA polymerase.
Consensus cycling parameters
The consensus thermal cycling conditions optimized to amplify
all amplicons of the 5 candidate genes under study simultaneously
on a Perkin Elmer (Oak Brook, IL) Gene-Amp 2400 thermocycler
were as follows: initial denaturation at 95°C for 3 min followed by
touch-down cycling at 95°C for 30 sec, 62°C for 1 min (incubation
temperature was reduced by 0.5°C each cycle up to 54°C and
incubation time by 1.0 sec each cycle) and 72°C for 30 sec. This
was followed by 15 additional cycles at 95°C for 30 sec, 54°C for
45 sec and 72°C for 30 sec.
Intensity plots
Human placental DNA in different concentrations was used as
template in multiplex PCR for all genes studied, and the intensity
of the low m.w. band vs. the high m.w. band was plotted. This was
used as a standard to verify the absence/presence of methylation in
the HpaII-treated genomic DNA samples.
RESULTS
To assess the methylation profile in cancer-related genes, we
designed primers, a pair flanking at least 1 HpaII (5CCGG3) site
and a seminested primer in the promoter region (DNA sequence up
to 500 bp upstream of the transcription start site; the CpGs of these
promoters are known to be hypermethylated in human cancers), of
the 5 genes used. The strategy involves digestion of the total
genomic DNA with restriction enzyme HpaII, followed by semi-
nested, multiplex PCR using primers designed for the promoter
region, the outer primers (sense and antisense) amplifying a prod-
uct flanking the restriction site for the enzyme while the product
generated by the seminested and the antisense primers is not
affected by the restriction digestion (Fig. 1). Appearance of 2
bands using enzyme-treated genomic DNA as template would
indicate methylation of the CpG site(s), while a single band am-
plified by the nested primer would indicate unmethylated DNA. A
consensus PCR condition was developed, which could be used to
detect the methylation status of the promoter regions of several
genes. A standard plot comparing the intensity of the 2 bands (one
generated by the sense and antisense primers and the other by
nested and antisense primer) using serial concentrations of
genomic DNA template was used to eliminate false-positives and
-negatives. For confirmation of the sensitivity of our strategy,
human placental DNA and a plasmid vector containing a p16
promoter insert were methylated in vitro using Sss1 methylase and
digested using HpaII as described and the precipitated DNA was
used as template in the multiplex PCR using the primer set for p16.
We detected methylated samples as appearance of both full-length
and nested products (Fig. 1b). Further, using a standard plot of the
intensities of the 2 amplicons, we also determined that the assay
could detect methylation in 20% of alleles using different dilutions
of the cloned p16 promoter (Fig. 2). Subsequently, the in vitro
methylated human placental DNA was used as a template to test
FIGURE 3 – Verification of complete HpaII digestion. Representative
figure showing PCR products obtained using primers for human pro-
tein phosphatase flanking a single HpaII site. Lanes 1–10, HpaII-
digested DNA template; lanes 11–15, undigested controls.
FIGURE 4 – Agarose gel electrophoretic pattern of hypermethylation.
Representative samples of promoter hypermethylation for the 5 genes
are shown. Hypermethylation-positive cases are marked with arrows.
FIGURE 5 – Incidence of promoter hypermethylation. The percent-
age incidence for the genes p16, hMLH1, MGMT and E-cad in 99
OSCC samples and p15 in 51 samples is shown.
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TABLE II – CONSOLIDATED DATA SHOWING THE PROMOTER HYPERMETHYLATION PATTERN OF 5 GENES IN OSCC
AND CORRELATION WITH OTHER GENE ALTERATIONS STUDIED IN THE LAB
Number Sample
Epigenetic alterations
Promoter hypermethylation analysis
Genetic alterations
Mutation and deletion analysis
p16 p15 hMLH MGMT E-Cad p5323,24 ras21 p1626 p14arf25 Fhit30
1 O1
2 O7
3 O13 del
4 O21
5 O22 A-G del
6 O23 del
7 O25 G-A
8 O28 G-C
9 O29
10 O30
11 O35
12 O37
13 O41
14 O43
15 O44
16 O57 C-T
17 O58
18 O59 A-G
19 O65
20 O129
21 O127
22 O126
23 O124
24 O92
25 v1
26 v2
27 v3
28 v4
29 v5
30 v6
31 v7
32 v8
33 v10
34 v11
35 v12
36 v13
37 v14
38 v15
39 v16
40 v17
41 v18
42 v19
43 v20
44 v21
45 v22
46 v23
47 v24
48 v25
49 v26
50 v27
51 v28
52 1
53 2 T-C
54 3 T-C
55 4
56 5
57 6
58 7 T-C
59 8
60 9
61 10
62 11
63 12 G-A
64 13
65 14
66 15 G-T
67 16
68 17 G-T
69 18
70 19
71 20
72 21
73 22
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for the other genes. Ninety-nine surgically resected OSCC cases
were studied to assess promoter hypermethylation in 4 genes, p16,
MGMT, hMLH1 and E-cadherin; and 51 samples of these were
checked for methylation of the p15 promoter region.
The extent of digestion of the DNA samples by HpaII was
assessed using sense and antisense primers designed flanking a
single HpaII site in the exon 1 region of the human protein
phosphatase gene. Complete digestion was indicated by absence of
the amplicon compared to undigested control DNA. The same
HpaII-treated DNA samples verified by the above process were
used to study for promoter hypermethylation in all of the genes
studied (Fig. 3).
The percentage incidence of promoter hypermethylation was
23% for both p15 and p16. In the case of hMLH1, promoter
hypermethylation was detected, albeit in a lower number (8%) of
OSCC cases. The promoter region of E-cadherin was hypermethy-
lated in 35% of individuals, and aberrant hypermethylation inci-
dence was the highest in 41% of cases for the MGMT promoter
(Figs. 4,5). For the 51 samples in which methylation status of all
5 genes was studied, 74.5% of cases showed methylation for at
least 1 of the genes studied, 40% for 2 of the genes and 16% for
3 of the genes; only 1 sample showed methylation in 4 genes. For
the 99 samples in which methylation status of 4 genes were
studied, 72% showed aberrant methylation for at least 1 of the
genes, 29% for 2 of the genes, 7% for 3 of the genes and 0 for all
4 genes (Table II).
Twenty-five normal samples of squamous tissue of the oral
cavity were also included, which did not show any aberrant hy-
permethylation in the promoter region for the genes studied.
No significant correlation was observed in the hypermethylation
pattern of 2 different genes in OSCC; i.e., for the genes used here,
a methylation event in the promoter region of 1 gene was not
significantly associated with promoter hypermethylation of any
other gene.
DISCUSSION
Methylation is a major epigenetic modification in humans, and
changes in methylation patterns play an important role in tumor-
igenesis.2,6 Regions that are frequent targets for hypermethylation
events are CpG islands. CpG islands are GpC- and CpG-rich
regions of approximately 1 kb that are usually associated with the
promoter or 5 end of genes.6 Abnormal methylation of CpG
islands can efficiently repress transcription of the associated gene
in a manner akin to mutations and deletions and act as one of the
“hits” in Knudson’s 2-hit hypothesis for tumor generation.6 Tumor
cells exhibit global hypomethylation of the genome accompanied
by region-specific hypermethylation events.6
In our study, we analyzed only specific CpGs that are generally
observed to be aberrantly methylated in human cancers, and this
may limit our methylation profile data since methylation patterns
of CpGs have been observed to be heterogeneous in their occur-
rence; i.e., in a particular cancer type, CpG sites methylated in one
patient need not be the same as in another patient.19 A true
methylation profile could be generated by bisulfite sequencing, but
this would be a cumbersome technique for studying a panel of
genes in a large number of samples.
In human OSCC, a profile indicating the extent of methylation
of tumor-associated genes remains largely unknown. Our studies
indicate that the repair genes MGMT and E-cadherin are the most
preferentially targeted genes for methylation in OSCC of Indians
(Table II). Previous studies have indicated a positive correlation
between tobacco carcinogens and MGMT hypermethylation.1 In-
activation of MGMT leads to transition mutations indicated by
accumulation of high levels of mutations of this type in oncogenes
and tumor-suppressor genes.20 Point mutations in the ras gene
corresponded with promoter hypermethylation of the MGMT gene
in 60% (3/5) of cases out of 48 samples in which the ras mutation
status was studied,21 and for the 67 samples in which mutation
status of the p53 was known,22,23 the correlation between the
transition mutations in p53 and promoter hypermethylation of
MGMT gene was 3 of 7 (43%) (Table II).
The INK4A locus is altered in a majority of cancer types,
including OSCCs;24,25 specifically, the p16 tumor-suppressor gene
is altered in virtually all tumors. The levels of hypermethylation
observed in OSCC are consistent with those observed by other
workers in head-and-neck cancer.20 Previous studies from our
laboratory indicated that mutations were infrequent in this gene in
TABLE II – CONSOLIDATED DATA SHOWING THE PROMOTER HYPERMETHYLATION PATTERN OF 5 GENES IN OSCC
AND CORRELATION WITH OTHER GENE ALTERATIONS STUDIED IN THE LAB (CONTINUED)
Number Sample
Epigenetic alterations
Promoter hypermethylation analysis
Genetic alterations
Mutation and deletion analysis
p16 p15 hMLH MGMT E-Cad p5323,24 ras21 p1626 p14arf25 Fhit30
74 23
75 24
76 25
77 26
78 27
79 28
80 29 C-T
81 30
82 31
83 32
84 T1
85 T2 G-T C-T
86 T3
87 T4
88 T5
89 T6
90 T7
91 T8
92 T9
93 T10 G-A
94 T11
95 T12
96 T13 4bp del
97 T14 T-G
98 T15
99 T16
Gray boxes, analyzed; white boxes, not analyzed; black boxes, methylated. Superscript numbers in column heads are references cited.
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OSCC.26 High incidence of hypermethylation in the promoter
region of this gene is indicative of alternate mechanisms of inac-
tivation. Our observations also indicate that the 2 inactivating
events, mutations and promoter hypermethylation, in the p16 gene
did not occur simultaneously in the cases analyzed (Table II).
We have observed a very low incidence of promoter hypermeth-
ylation of the hMLH1 gene, which is involved in mismatch repair
function. Loss of expression of this gene leads to genomic insta-
bility, manifested in the form of microsatellite instabilities. Low
levels of methylation inactivation of hMLH1 indicated in our study
are consistent with the observation of very low incidence of
microsatellite instability in OSCC.27–29
The main conclusion of our study is that even though the
promoter regions of multiple genes could be methylated in an
OSCC case, there is no significant correlation in occurrence of
promoter hypermethylation between any 2 of the genes studied
here. This indicates that promoter hypermethylation might be a
random, rather than a targeted, event. The question that remains
unanswered is how only specific subsets of genes are hypermethy-
lated in particular cancer types.
The technique devised by us is simple and straightforward; and
though problems due to incomplete digestion are likely to arise,
use of reliable genomic DNA purification techniques, standardiza-
tion of PCR sensitivity by reducing end cycles and use of a
standard plot curtail false-positives. In our study, the occurrence of
false-positives was ruled out as verified by PCR using primers
flanking a single HpaII site in the human protein phosphatase gene
and further indicated by the fact that none of the samples was
positive for all of the genes tested using the same restriction-
digested DNA as template.
The studies described here using 5 genes indicate that aberrant
promoter hypermethylation occurred in at least 1 of the genes in
74.5% of cases. Our studies suggest that epigenetic mechanisms
could play a major role and in some cases may even supersede
genetic events in the inactivation of certain tumor-suppressor and
tumor-associated genes in the genesis of OSCC.
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